The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can and or wants to take them. In this episode, which is based on Goldman Sachs Research’s latest Top of Mind report, obesity medicine physician Dr. Fatima Cody Stanford and Jonathan Gruber, professor of economics and chairman of the Economics Department at MIT, discuss how large the addressable market for GLP-1s actually is and the implications for US fiscal health.
If you want more insights from Goldman Sachs, make sure to visit GS.com and sign up for Briefings, a weekly newsletter from Goldman Sachs about trends spanning markets, industries, and the global economy.
Markets Update: September Turbulence
Pandemic Perspectives: Insights from Our First Virtual Intern Class
Markets Update: European Leveraged Capital Markets
Exploring the Founder Journey with Launch With GS CEOs
Markets Update: Subdued Mood as S&P 500 Hits Record Highs
The Latest Outlook for U.S. Equities
Markets Update: U.S. Election in Focus
Why Diversity Drives Better Investment Performance
Markets Update: SPACs
How Companies Are Meeting Their Financing Needs
Markets Update: Balanced Bear Repair
How Automated Robots are Supporting the Surge in E-commerce
Markets Update: Europe’s Fiscal Stimulus
Where CIOs are Allocating Capital, According to GSAM’s 2020 Insurance Report
Markets Update: A “Gritty” Second Quarter
Sustainable ESG Investing: Turning Promises into Performance
Markets Update: "Investor Sobriety" Carries into Q3
U.S. Dollar Weakness
Markets Update: Banks’ Stress Tests
What’s Driving Growth in Alternative Asset Classes?
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
TED Radio Hour
FT Alphachat
Freakonomics Radio
Odd Lots
Slate Money